Literature DB >> 10981089

The World Health Organization--International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments.

B Neal1, S MacMahon.   

Abstract

Clear evidence shows that decreasing blood pressure reduces risks for major cardiovascular events in patients with hypertension. However, there is considerable uncertainty about the separate effects of the various classes of blood pressure-lowering agents and the effects of blood pressure lowering in patients at high risk, particularly in the absence of hypertension. Several new randomized controlled trials have been started in the past few years in an effort to address these questions. However, individually, these studies are unlikely to resolve all current uncertainties. For this reason, systematic overviews and meta-analyses of the major ongoing trials are planned. The overviews will be conducted as a collaboration among the principal investigators of the participating trials and will involve about 270,000 patients and 1.1 million patient-years of follow-up. The combined trial results should provide good statistical power to detect even modest differences in the effects of various treatments on major cardiovascular outcomes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10981089     DOI: 10.1007/s11906-999-0045-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  58 in total

1.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

2.  Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.

Authors:  K K Teo; J R Burton; C Buller; S Plante; S Yokoyama; T J Montague
Journal:  Can J Cardiol       Date:  1997-06       Impact factor: 5.223

Review 3.  Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-15

4.  Action: a 30,000 patient-years double-blind, placebo-controlled trial of nifedipine GITS in stable angina. ACTION Research Group.

Authors:  J Lubsen; P A Poole-Wilson
Journal:  Br J Clin Pract Suppl       Date:  1997-04

5.  Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.

Authors: 
Journal:  J Hypertens       Date:  1998-02       Impact factor: 4.844

6.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.

Authors: 
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

7.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

Review 8.  The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension.

Authors: 
Journal:  Blood Press       Date:  1993-12       Impact factor: 2.835

9.  Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration.

Authors: 
Journal:  Am J Cardiol       Date:  1995-06-01       Impact factor: 2.778

10.  The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.

Authors: 
Journal:  Can J Cardiol       Date:  1996-02       Impact factor: 5.223

View more
  5 in total

Review 1.  Establishing targets for hypertension control in patients with comorbidities.

Authors:  Carlos Feldstein; Stevo Julius
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

2.  Impact of a NDUFC2 Variant on the Occurrence of Acute Coronary Syndromes.

Authors:  Giovanna Gallo; Serena Migliarino; Maria Cotugno; Rosita Stanzione; Simone Burocchi; Franca Bianchi; Simona Marchitti; Camillo Autore; Massimo Volpe; Speranza Rubattu
Journal:  Front Cardiovasc Med       Date:  2022-05-31

3.  INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.

Authors:  Rhonda M Cooper-DeHoff; Eileen M Handberg; Giuseppe Mancia; Qian Zhou; Annette Champion; Udo F Legler; Carl J Pepine
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-11

4.  Adverse Reaction of Acupuncture and Antihypertensive Drugs for Treatment of Essential hypertension: A Protocol for Bayesian Network Meta-Analysis.

Authors:  Jiawei Han; Jiwei Yang; Yuanhao Du
Journal:  Comput Intell Neurosci       Date:  2022-08-21

5.  Atrial natriuretic Peptide single nucleotide polymorphisms in patients with nonfamilial structural atrial fibrillation.

Authors:  Pietro Francia; Agnese Ricotta; Alessandra Frattari; Rosita Stanzione; Anna Modestino; Federico Mercanti; Carmen Adduci; Isabella Sensini; Maria Cotugno; Cristina Balla; Speranza Rubattu; Massimo Volpe
Journal:  Clin Med Insights Cardiol       Date:  2013-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.